Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Kifle, Bruck (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S299000, C540S520000, C546S183000
Reexamination Certificate
active
08008288
ABSTRACT:
The invention provides compounds, compositions, and uses of compounds of general formula (I) or pharmaceutically acceptable salts thereof, for the preparation of a medicament intended to treat an inflammatory disorder wherein y is any integer from 1 to 8; z is any integer from 1 to 8; with the proviso that y and z cannot both equal 1; X is —C —(Y)k—(R1)nor SO2—(Y)k—(R1)n; k is 0 or 1; Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group); or Y is a cycloalkenyl or polycycloalkenyl group.
REFERENCES:
patent: 6395282 (2002-05-01), Kende et al.
patent: 2008/0161283 (2008-07-01), Grainger
patent: 10305922 (2004-03-01), None
patent: 10265761 (1998-10-01), None
patent: WO-97/17362 (1997-05-01), None
patent: WO 99/12968 (1999-03-01), None
patent: WO 00/42071 (2000-07-01), None
patent: W02005/053702 (2005-06-01), None
patent: W02005/077900 (2005-08-01), None
patent: WO-2006/018609 (2006-02-01), None
patent: W02006/024815 (2006-03-01), None
“International Preliminary Report on Patentability for corresponding PCT Application No. PCT/GB2005/003139”, (Feb. 20, 2007), 8 pgs.
“International Search Report for corresponding PCT Application No. PCT/GB2005/003139”, (Feb. 9, 2006), 5 pgs.
“UK Search Report Under Section 17 for Patent Application No. GB0418375.2”, (Nov. 29, 2004),1 pg.
Asao, T., et al., “Structure of Reaction Products of 5-Nitrosotropolone and Arylamine”,Chemical Abstracts—No. 114:143076, (1990), 2 pgs.
Asao, T., et al., “Structure of Reaction Products of 5-Nitrosotropolone and Arylamine”,Bulletin of the Chemical Society of Japan, 63(11), (1990),3089-3095.
Hughes, P., et al., “Total Synthesis of Cyclobutane Amino Acids FromAtelia herbert smithii”, Journal of Organic Chemistry, 53(20), (1988), 4793-4796.
Paquette, L. A., et al., “Addition Reactions of the Uniparticulate Electrophile Chlorosulfonyl isocyanate to Highly Strained Bicyclic Hydrocarbons”,Journal of the American Chemical Society, 93(18), (1971), 4503-4508.
Zahn, H., et al., “DL-Hydroxylysine and DL-Allohydroxylysine and Their Lactones”,Chemische Berichte, 91, (1958),1359-1371.
Fetzion et al., Synthese dans las serie d'alcoyl-4 aza-2 bicyclo-(2,2,2) octane, Bull. Soc. Chim. Fr. (1969) No. 1, pp. 194 -197.
Gould, “Salt selection for basic drugs”, Int. J. Pharm. (1986), 33, 201-217.
Weiss et al., “Effects of Various Amides on a Rat Brain Puromycin-sensitive Aminopeptidase and on Induced Convulsions in Mice”, Research Communications in Psychology, Psychiatry and Behavior (1992), 17(3-4), pp. 153-159.
Reckless et al., “Identification of Oligopeptide Sequences which Inhibit migration induced by a wide range of chemokines”, Biochem J. (1999) 340:803-811.
Fox et al., “Design, Synthesis, and Preliminary Pharmacological Evaluation of N-Acyl-3-aminoglutarimides as Broad-Spectrum Chemokine Inhibitors in Vitro and Anti-inflammatory Agents in Vivo”, J. Med. Chem. 45(2002) 360-370.
Grainger et al., “Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo”, Biochem. Pharm. 65 (2003) 1027-1034.
Boyle, et al., “Asymmetric Transformation of alpha-Amino-epsilon-caprolactam, a Lysine Precursor”, J. Org. Chem., vol. 44, (1979), pp. 4841-4847.
Kuo, et al., “Calcium-dependent protein kinase: Widespread occurrence in various tissues and phyla of the animal kingdom and comparison of effects of phospholipid, calmodulin, and trifluoroperazine”, Proc. Natl. Acad. Sci. USA, vol. 77, pp. 7039-7043, (1980).
Rezler et al., “Preparation, Characterization, DNA Binding, and in Vitro Cytotoxicity of the Enantiomers of the Platinum (II) Complexes N-Methyl-, N-Ethyl- and N,N-Dimethyl-(R)- and -(S)-3-aminohexahydroazepinedichloroplatinum(II)”, J. Med. Chem, 40, 3508-3515, (1997).
Fetizon et al., Synthese dans las serie d'alcoyl-4 aza-2 bicyclo-(2,2,2) octane, Bull. Soc. Chim. Fr. (1969) No. 1, pp. 194-197 (Note: This Listing Corrects the Spelling of the First-Named Author, But Is Otherwise Duplicative of Citation #1 on Form SB08 Filed Oct. 1, 2010).
Davidson, B.S., “Isolation and synthesis of caprolactins A and B, new caprolactams from a marine bacterium”, Tetrahedron, 49(30), 6569-6574 (1993).
Grainger, D.J., et al., “Broad spectrum chemokine inhibitors related to NR58-3.14.3”, Mini-Reviews in Medicinal Chemistry, 5(9), 825-32 (2005).
Fox, D. J., et al., “Identification of 3-(Acylamino)azepan-2-ones as Stable Broad-Spectrum Chemokine Inhibitors Resistant to Metabolism in Vivo”, J. Med. Chem., 48, 867-874 (2005).
Fox, D. J., et al., “Supporting Information—Identification of 3-(Acylamino)azepan-2-ones as Stable Broad-Spectrum Chemokine Inhibitors Resistant to Metabolism in Vivo”, J. Med. Chem., S1-S6, (2005).
Fox David John
Grainger David J.
Bone Richard G. A.
Cambridge Enterprise Limited
Kifle Bruck
VLP Law Group LLP
LandOfFree
Anti-inflammatory A-aminocyclolactam compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory A-aminocyclolactam compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory A-aminocyclolactam compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2650130